新型抗病毒药物法匹拉韦（T-705）治疗发热伴血小板减少综合征（SFTS）。
Severe fever with thrombocytopenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705).
机构信息
Center of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, 8 Jingshun East Street, Chaoyang District, 100015, Beijing, People's Republic of China.
Cancer Center, Beijing Ditan Hospital, Capital Medical University, 8 Jingshun East Street, Chaoyang District, 100015, Beijing, People's Republic of China.
出版信息
Infection. 2020 Apr;48(2):295-298. doi: 10.1007/s15010-019-01364-9. Epub 2019 Oct 31.
BACKGROUND
Severe fever and thrombocytopenia syndrome (SFTS) is an acute illness with a high mortality (16.2-29.1%). Unfortunately, there is no specific cure or vaccine for SFTS.
METHODS
In this open-label study, two patients with SFTS were treated with favipiravir, a new antiviral drug.
RESULTS
Patients had a sustainable virologic, immunologic and symptomatic recovery.
CONCLUSIONS
Favipiravir may be a prosiming drug for the treatment of SFTS.
背景
严重发热伴血小板减少综合征（SFTS）是一种具有高死亡率（16.2-29.1%）的急性疾病。不幸的是，目前还没有针对 SFTS 的特效疗法或疫苗。
方法
在这项开放性标签研究中，两名 SFTS 患者接受了一种新型抗病毒药物——利巴韦林的治疗。
结果
患者的病毒学、免疫学和症状均得到持续恢复。
结论
利巴韦林可能是治疗 SFTS 的一种有前景的药物。
Zotero 插件